<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03469102</url>
  </required_header>
  <id_info>
    <org_study_id>Impact Texture Surr√©nale</org_study_id>
    <nct_id>NCT03469102</nct_id>
  </id_info>
  <brief_title>18FDG PET Textural Indices in Adrenal Lesion</brief_title>
  <acronym>ImpactTexture</acronym>
  <official_title>Diagnostic Value of 18FDG PET/CT Textural Indices in Patients With an Adrenal Lesion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tumors are characterized by a great heterogeneity. Characterizing this intra-tumor&#xD;
      heterogeneity is a major challenge in oncology to improve the therapeutic management and move&#xD;
      towards personalized medicine adapted to each patient. However, intra-tumor heterogeneity&#xD;
      remains rarely used for diagnostic purposes The discovery of an adrenal mass can occur in&#xD;
      different circumstances. Detection of an adrenal mass can be done in a context of secreting&#xD;
      syndrome, in the assessment of an extra-adrenal neoplasia or fortuitously when performing an&#xD;
      imaging for another reason. The etiologies are numerous (cortical tumors, medullary tumors,&#xD;
      metastatic lesion of a extra-adrenal neoplasia, others). The adrenal masses can be divided&#xD;
      into two categories, depending on whether they are hyperfunctional or not. In patients&#xD;
      without an oncological history, an adrenal mass discovered is most often a benign adenoma,&#xD;
      but requires an endocrine assessment. In patients with known primary cancer, approximately&#xD;
      30% of the adrenal masses are malignant.&#xD;
&#xD;
      In all cases, the diagnostic procedure includes an imaging assessment to characterize the&#xD;
      lesion and an endocrine assessment. CT scan performed without and after intravenous iodinated&#xD;
      contrast agent injection is the first-line examination to assess an adrenal mass.&#xD;
&#xD;
      18F-FDG-PET may be indicated as second-line for characterizing an adrenal mass. Adrenal tumor&#xD;
      SUVmax (Standard Uptake Value) and adrenal tumor SUVmax / liver SUVmax ratio are routinely&#xD;
      used to determine the malignancy of a lesion. Although very useful for assessing the glucose&#xD;
      metabolism of a given lesion, these parameters do not allow assessing the heterogeneity of&#xD;
      tumor uptake. The texture analysis corresponds to an analysis of the spatial distribution of&#xD;
      FDG uptake, and allows, by the calculation of many indices, an evaluation of the&#xD;
      heterogeneity of the tumors.&#xD;
&#xD;
      The hypothesis of our study is that the texture parameters could have an additional&#xD;
      diagnostic value to improve the performance of conventional quantitative parameters to&#xD;
      determine the malignancy of a lesion.&#xD;
&#xD;
      The objective of this study is to investigate the diagnostic value of texture indices in a&#xD;
      large cohort of patients presenting an adrenal lesion&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Actual">July 27, 2018</completion_date>
  <primary_completion_date type="Actual">July 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic performance of FDG PET/CT textural indices</measure>
    <time_frame>6 months</time_frame>
    <description>Area Under the Curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cut off value of FDG PET/CT textural indices</measure>
    <time_frame>6 months</time_frame>
    <description>For each cut off value : Sensibility(%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cut off value of FDG PET/CT textural indices</measure>
    <time_frame>6 months</time_frame>
    <description>For each cut off value : Specificity(%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cut off value of FDG PET/CT textural indices</measure>
    <time_frame>6 months</time_frame>
    <description>For each cut off value : Positive and Negative Predictive Value (%),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cut off value of FDG PET/CT textural indices</measure>
    <time_frame>6 months</time_frame>
    <description>For each cut off value : Accuracy (%)</description>
  </secondary_outcome>
  <enrollment type="Actual">53</enrollment>
  <condition>Adrenal Tumor</condition>
  <eligibility>
    <study_pop>
      <textblock>
        presenting an adrenal lesion&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having benefited from a 18-FDG PET-CT scan in the nuclear medicine department of&#xD;
             University Hospital of Brest&#xD;
&#xD;
          -  Addressed in the context of an assessment of an adrenal lesion, in the evaluation of&#xD;
             an extra-adrenal neoplasia or other motive&#xD;
&#xD;
          -  presenting an adrenal lesion&#xD;
&#xD;
          -  From June 29, 2012 to June 30, 2017&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients followed in another center than the University Hospital of Brest&#xD;
&#xD;
          -  Lesions of undetermined nature&#xD;
&#xD;
          -  Diagnosis of benignity or malignancy not confirmed by anatomopathology.&#xD;
&#xD;
          -  Patient having expressed his opposition to the use of his medical data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2018</study_first_posted>
  <last_update_submitted>July 27, 2018</last_update_submitted>
  <last_update_submitted_qc>July 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Positron emission tomography</keyword>
  <keyword>Texture indices</keyword>
  <keyword>Diagnostic performance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Gland Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

